查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947954

Enzalutamide锭市场依治疗阶段、最终用户、适应症、通路和剂量划分，全球预测，2026-2032年

Enzalutamide Tablets Market by Therapy Line, End User, Indication, Distribution Channel, Dosage Strength - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Enzalutamide片剂市场价值将达到 37.2 亿美元，到 2026 年将成长至 38.8 亿美元，到 2032 年将达到 52.8 亿美元，复合年增长率为 5.10%。

关键市场统计数据
基准年 2025 37.2亿美元
预计年份：2026年 38.8亿美元
预测年份 2032 52.8亿美元
复合年增长率 (%) 5.10%

本文简要概述了Enzalutamide片剂的临床特征和相关人员趋势如何重塑治疗决策和获取途径。

Enzalutamide片已成为多种前列腺癌适应症的口服治疗主力药物，其临床特性持续影响治疗流程、支付方考量和采购惯例。本文概述了Enzalutamide片在现代肿瘤治疗中的作用，并重点阐述了其作用机制、给药便利性和不断扩大的适应症如何影响处方医生的决策和下游相关人员的行为。

对不断演变的临床证据、支付方评估框架以及供应链创新进行深入分析，这些因素正在重新定义口腔癌药物的采用和取得。

由于临床证据的不断完善、指南的更新以及以患者为中心的护理模式的广泛应用，Enzalutamide片剂的治疗格局正在发生变革性变化。随着新的临床试验结果不断完善口服雄性激素受体抑制剂的相对优势，临床医生正在重新调整治疗方案，并在某些患者群体中更早使用该类药物。这种转变促使人们更加关注耐受性管理、药物交互作用的监测以及能够保留后续治疗选择的治疗顺序策略。

从实际检验2025年美国关税政策变化如何影响癌症治疗药物供应的筹资策略、采购惯例和营运弹性

美国2025年实施的关税政策调整的累积效应，已对进口原料药和Enzalutamide片剂的成本动态和供应链结构产生了显着影响。製造商和经销商正采取措施降低进口关税带来的风险，包括重新评估其采购基地、协商修订后的供应商协议以及加快本地生产评估。这些调整需要采购、监管和销售团队之间的跨职能合作，以维持供应的连续性并确保商业性可行性。

多维細項分析揭示了治疗线、终端使用者组成、适应症组成、通路和剂量强度如何影响需求驱动因素和营运重点。

关键細項分析揭示了按治疗方案、最终用户、适应症、分销管道和剂量强度分類的不同需求模式和相关人员优先事项。就治疗方案而言，第一线治疗方案的选择受最新指南更新和一线对照药物疗效的影响；二线治疗方案的使用反映了治疗顺序逻辑和既往激素暴露史；三线治疗方案的趋势则受耐受性和累积暴露量的影响。这些临床决策因素直接影响采购频率和药品目录协商。

从全面的区域观点阐述监管多样性、支付方框架和分销基础设施如何影响美洲、欧洲、中东和非洲以及亚太地区的准入策略。

区域趋势将显着影响美洲、欧洲、中东和非洲以及亚太地区的医疗服务取得途径、监管应对措施和商业策略。在美洲，重点在于整合医疗系统与私人支付者之间的谈判，这将指导药品目录的製定和病患援助计画的设计。同时，集中式集团采购组织和大型医院网路在竞标结果和采购速度方面发挥关键作用。过渡性政策和区域报销框架要求制定客製化的价值提案，使临床数据与支付方特定的疗效指标相符。

对产业相关人员为保持差异化优势和扩大口服抗癌药物的可及性而采取的竞争策略、伙伴关係模式和监管应对措施进行评估性总结

主要企业的竞争策略和企业策略体现了生命週期管理、实证医学证据产生和伙伴关係模式的结合，旨在保持临床差异化并扩大市场准入。创新企业优先进行长期安全性和疗效比较研究，以支持扩大适应症并维持其在药品目录中的地位，同时也投资于病患援助计画和数位依从性解决方案。同时，寻求学名药和生物相似药途径的企业则专注于扩大生产规模、提交监管替代性文件以及製定具有竞争力的定价策略，以抢占对价格最敏感的细分市场。

为商业、临床和供应链领导者提供切实可行的策略挑战，以协调证据产生、合约签订和采购，从而实现稳健的市场准入和应用。

为确保持续的市场可及性和临床应用，产业领导者应优先考虑整合临床证据、商业策略和供应链韧性的方法。首先，他们应投资于有针对性的证据生成，以满足支付方定义的价值标准和临床医生的关注点。这包括真实世界安全性监测和病患报告结果（PRO），从而加强处方笺和指南采纳的证据基础。其次，他们应实现采购多元化，并考虑建立策略性製造伙伴关係，以降低关税风险和物流中断的影响，同时确保产品品质和合规性。

透明的检验调查方法框架，详细说明了关键相关人员的参与、二手证据的综合、三角测量技术以及用于产生可操作结果的验证程序。

这些研究结果所依据的调查方法结合了对同行评审的临床文献、指南声明和监管文件的系统性回顾，以及对透过针对临床医生、医院药剂师、采购专业人员和行业高管的访谈收集到的相关人员观点的结构化综合分析。主要定性访谈旨在了解不同医疗机构的决策驱动因素、未满足的需求和营运挑战，而次要资讯则提供了临床和监管背景，以便准确解读相关人员的观点。

权威的综合分析强调，需要采取临床、商业和运作相结合的综合方法，以确保患者获得治疗并持续接受治疗。

总之，Enzalutamide片剂目前面临的挑战包括：临床进展不断汇聚、支付方预期不断变化，以及贸易政策和分销动态导致营运复杂性日益增加。积极主动地将循证医学证据与支付方需求相结合、加强供应链冗余、并根据不同终端用户的行为调整商业性策略的相关人员，将更有利于维持药物可及性并支持患者获得可持续的治疗效果。临床定位、采购机制和区域监管差异之间的相互作用，需要製定针对特定国家的细化实施计划，并辅以集中化的策略监督。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Enzalutamide片剂市场依治疗阶段划分

  • 一线治疗
  • 二线治疗
  • 三线治疗

第九章Enzalutamide片剂市场：依最终用户划分

  • 医院药房
  • 零售药房
  • 专科诊所
    • 肿瘤诊所
    • 泌尿系统诊所

第十章Enzalutamide片剂市场依适应症划分

  • 转移性去势去势抗性前列腺癌
  • 转移性荷尔蒙敏感性前列腺癌
  • 非转移性去势抗性前列腺癌

第十一章Enzalutamide片剂市场（依分销管道划分）

  • 在线的
    • 製造商官方网站
    • 电子商务平台
  • 离线

第十二章Enzalutamide片剂市场：依剂量划分

  • 120 mg
  • 160 mg
  • 40 mg
  • 80 mg

第十三章Enzalutamide锭市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章Enzalutamide片剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国Enzalutamide锭剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国：Enzalutamide片市场

第十七章：中国Enzalutamide片市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Healthcare Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hetero Labs Limited
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Lupin Limited
  • Mylan NV
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FB6A4

The Enzalutamide Tablets Market was valued at USD 3.72 billion in 2025 and is projected to grow to USD 3.88 billion in 2026, with a CAGR of 5.10%, reaching USD 5.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.72 billion
Estimated Year [2026] USD 3.88 billion
Forecast Year [2032] USD 5.28 billion
CAGR (%) 5.10%

A concise strategic overview of how the clinical profile and stakeholder dynamics of enzalutamide tablets are reshaping treatment decisions and access pathways

Enzalutamide has emerged as a cornerstone oral therapy across multiple prostate cancer indications, and its clinical profile continues to shape treatment algorithms, payer deliberations, and procurement practices. This introduction outlines the therapeutic role of enzalutamide within contemporary oncology care, highlighting how its mechanism of action, administration convenience, and evolving label expansions inform prescriber decision making and downstream stakeholder behavior.

Practicing clinicians, hospital pharmacists, and specialty clinic teams are navigating an increasingly complex intersection of efficacy evidence, tolerability considerations, and health system budget pressures. Consequently, understanding the pathway from clinical trial results to real-world prescribing patterns is essential for manufacturers and distributors aiming to optimize product access and continuity of supply. Moreover, the interdependencies between regulatory updates, guideline revisions, and payer coverage rules necessitate a clear, evidence-based narrative to support adoption.

Finally, this introduction frames the subsequent sections: the shifting landscape of treatment paradigms, trade and tariff implications, segmentation-based demand drivers, regional dynamics, competitive positioning, strategic recommendations, and the research approach used to assemble these insights. Taken together, these elements provide a foundation for actionable strategy without presuming one-size-fits-all solutions, instead emphasizing context-specific planning and cross-stakeholder alignment.

An in-depth analysis of evolving clinical evidence, payer assessment frameworks, and supply chain innovations that are redefining adoption and access for oral oncology therapies

The therapeutic landscape for enzalutamide is experiencing transformative shifts driven by clinical evidence maturation, guideline updates, and a broader emphasis on patient-centric care models. As new trial outcomes refine the comparative positioning of oral androgen receptor inhibitors, clinicians are recalibrating line-of-therapy decisions and integrating earlier use in certain patient cohorts. This progression is accompanied by a heightened focus on tolerability management, drug-drug interaction vigilance, and sequencing strategies that preserve subsequent therapeutic options.

Concurrently, payers and health technology assessment bodies are adopting more granular value frameworks that consider not only clinical endpoints but also patient-reported outcomes and real-world safety profiles. These evolving assessment criteria are prompting manufacturers and providers to generate differentiated evidence packages that speak to long-term disease control, quality-of-life measures, and care pathway efficiencies. In parallel, digital health tools and remote monitoring practices are supporting adherence and toxicity surveillance, enabling more decentralized models of follow-up care that can affect refill patterns and distribution channel utilization.

Supply chain resilience and procurement sophistication also represent transformative levers. Stakeholders increasingly design contingency plans, diversify sourcing, and negotiate value-based agreements that align financial incentives with clinical outcomes. Taken together, these shifts underscore the need for integrated strategies that combine clinical leadership, payer engagement, and operations planning to secure durable access and to optimize patient outcomes in a dynamic therapeutic environment.

A pragmatic examination of how 2025 tariff shifts in the United States have reshaped sourcing strategies, procurement practices, and operational resilience for oncology drug supply

The cumulative effect of tariff policy changes implemented in 2025 in the United States has materially altered cost dynamics and supply chain design for imported active pharmaceutical ingredients and finished-dose enzalutamide tablets. Manufacturers and distributors have responded by reassessing sourcing footprints, negotiating revised supplier contracts, and accelerating local manufacturing evaluations to mitigate exposure to import duties. These adjustments have required cross-functional coordination across procurement, regulatory affairs, and commercial teams to maintain continuity of supply while preserving commercial viability.

From a procurement perspective, hospitals and specialty clinics have reevaluated tender strategies and inventory buffering practices to account for increased landed costs and potential lead-time variability. Meanwhile, distributors and third-party logistics providers have expedited network redesigns that prioritize tariff-efficient routing and consolidation opportunities. In some cases, companies have explored contractual pass-through mechanisms or supplier co-investment models to stabilize gross margins without compromising patient access.

Regulatory and compliance teams have been tasked with ensuring that any shifts in manufacturing location or supply chain partners adhere to current good manufacturing practices and product registration requirements. In addition, payer-contracting teams are working to reframe reimbursement conversations to reflect changed unit economics and to justify formulary positioning through robust value narratives. Ultimately, the 2025 tariff environment has reinforced the importance of integrated commercial-operational planning, where trade policy considerations are embedded in product lifecycle strategies and procurement negotiations.

A multidimensional segmentation analysis revealing how therapy line, end-user configuration, indication mix, distribution pathways, and dosage strengths shape demand drivers and operational priorities

Key segmentation insights reveal distinct demand patterns and stakeholder priorities when analyzed across therapy line, end user, indication, distribution channel, and dosage strength. When therapy line is considered, first-line therapy adoption is influenced by recent guideline updates and frontline comparator performance, second-line usage reflects sequencing logic and prior exposure to hormonal agents, and third-line therapy dynamics are shaped by tolerability and cumulative exposure concerns. These layers of clinical decision making directly inform purchasing cadence and formulary negotiations.

End-user segmentation shows different operational and procurement behaviors among hospital pharmacies, retail pharmacies, and specialty clinics. Hospital pharmacies include government and private hospital settings that often manage high-volume procurement cycles and institutional tendering procedures, while retail pharmacies divide between chain and independent outlets with differing purchasing power and refill logistics. Specialty clinics, encompassing oncology and urology clinics, tend to focus on therapy-specific clinical monitoring, adherence counseling, and direct patient support programs that affect prescription retention and follow-up care.

Indication-based differentiation underscores how metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer each present unique clinical objectives, monitoring requirements, and payer negotiation points. Distribution channel segmentation further nuances access pathways: direct tenders-operationalized through national and regional tenders-favor institutional procurement scale, hospital pharmacy purchases-whether via direct procurement or public tenders-reflect institutional buying practices, and online pharmacies-represented by manufacturer websites and third-party platforms-offer alternative fulfillment routes that influence patient convenience and adherence.

Finally, dosage strength segmentation across 120 mg, 160 mg, 40 mg, and 80 mg formulations impacts prescribing flexibility, inventory management, and unit-packaging strategies. Differences in strength availability can drive prescribing preferences when clinicians balance efficacy, tolerability, and pill burden, and can also influence packaging and distribution decisions to optimize shelf life and reduce waste. Collectively, these segmentation lenses provide a multidimensional view of where targeted commercial interventions and operational investments will yield the greatest return in access and patient support.

A comprehensive regional perspective describing how regulatory diversity, payer frameworks, and distribution infrastructures shape access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics significantly affect access pathways, regulatory navigation, and commercial tactics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, the emphasis on integrated health systems and private-payer negotiations steers formulary positioning and patient assistance program design, while centralized group purchasing organizations and large hospital networks play pivotal roles in tender outcomes and procurement cadence. Transitional policies and regional reimbursement frameworks necessitate tailored value communications that align clinical data with payer-specific outcome measures.

Across Europe, the Middle East & Africa, a heterogeneous regulatory landscape combines national health systems, private payers, and emerging reimbursement authorities, each of which evaluates clinical value through a mix of cost-effectiveness thresholds and real-world evidence. In many countries within this region, price negotiation and HTA-led assessments drive access timelines, requiring manufacturers to prepare locally relevant dossiers and to engage early with key opinion leaders to facilitate guideline inclusion. Moreover, supply chain considerations such as cold-chain capacity and regional distribution hubs influence inventory strategies and delivery reliability.

The Asia-Pacific region presents a diverse set of market access conditions ranging from highly regulated national procurement frameworks to liberalized private markets. Regulatory acceleration programs in certain jurisdictions can enable faster registrations, yet parallel importation practices and variable reimbursement pathways necessitate carefully sequenced market entry plans. Local manufacturing partnerships and strategic licensing arrangements often play a critical role in establishing sustainable supply, while patient support initiatives and digital adherence tools can be particularly effective in markets with decentralized care delivery. Taken together, these regional insights call for granular, country-level execution plans that respect regulatory nuance and payer expectations while leveraging broader regional synergies.

An evaluative synopsis of competitive maneuvers, partnership models, and regulatory strategies that industry players deploy to sustain differentiation and expand access for oral oncology agents

Competitive and corporate strategies among key companies reflect a mix of lifecycle management, evidence generation, and partnership models aimed at sustaining clinical differentiation and expanding access. Innovator companies prioritize long-term safety and comparative-effectiveness studies to support label expansions and to defend formulary placement, while also investing in patient support programs and digital adherence solutions. At the same time, players exploring generic or biosimilar pathways focus on manufacturing scale-up, regulatory interchangeability dossiers, and competitive pricing strategies to capture segments where cost sensitivity is highest.

Strategic collaborations between manufacturers, contract manufacturers, and distribution partners are increasingly common, enabling flexible scale management and improved responsiveness to demand variability. Licensing and co-promotion agreements can facilitate market entry in jurisdictions with complex regulatory or reimbursement landscapes, while joint ventures for local production address both tariff exposure and supply continuity. In addition, some companies are experimenting with value-based contracting or outcomes-linked agreements to share risk with payers and to strengthen real-world evidence generation.

Finally, intellectual property considerations, patent expiry timelines, and defensive life-cycle tactics such as new formulations or indication expansions inform the competitive calculus. Robust pharmacovigilance programs and proactive stakeholder engagement strategies bolster trust across clinicians and payers, while operational excellence in quality systems and regulatory compliance remains a non-negotiable foundation for maintaining market access and reputational integrity.

Actionable strategic imperatives for commercial, clinical, and supply chain leaders to align evidence generation, contracting, and sourcing for resilient access and adoption

Industry leaders should prioritize an integrated approach that aligns clinical evidence, commercial strategy, and supply chain resilience to secure durable access and to capture clinical adoption opportunities. First, invest in targeted evidence generation that addresses payer-defined value criteria and clinician concerns, including real-world safety monitoring and patient-reported outcomes, thereby strengthening the narrative for formulary inclusion and guideline engagement. Second, diversify sourcing and consider strategic manufacturing partnerships to mitigate tariff exposure and logistical disruptions while maintaining quality and regulatory compliance.

Next, tailor market access playbooks to end-user characteristics and distribution realities, recognizing that hospital pharmacies, retail pharmacies, and specialty clinics each require distinct support models ranging from institutional tender navigation to outpatient adherence programs. Additionally, prepare region-specific tactics that reflect local regulatory expectations and payer decision frameworks; in many cases, early engagement with key opinion leaders and health authorities will accelerate acceptance and reduce access friction. Finally, adopt flexible contracting approaches-such as performance-linked agreements or patient support co-funding-that align incentives across stakeholders and protect patient continuity of care.

By operationalizing these recommendations through cross-functional governance, centralized scenario planning, and prioritized investment in evidence and logistics, industry leaders can navigate uncertainty more effectively and convert clinical value into sustainable patient access.

A transparent methodological framework detailing primary stakeholder engagement, secondary evidence synthesis, triangulation techniques, and validation steps used to generate actionable findings

The research methodology underpinning these insights combined a systematic review of peer-reviewed clinical literature, guideline statements, regulatory documents, and a structured synthesis of stakeholder input gathered through targeted interviews with clinicians, hospital pharmacists, procurement specialists, and industry executives. Primary qualitative interviews were designed to surface decision drivers, unmet needs, and operational pain points across care settings, while secondary sources provided the clinical and regulatory context necessary to interpret stakeholder perspectives accurately.

Data triangulation was applied to reconcile differences between reported clinical trial outcomes and real-world practice patterns, and to validate thematic findings across multiple respondent groups. Analytical frameworks included segmentation mapping, supply chain risk assessment, and payer evidence gap analysis, each of which was used to translate observations into practical implications. The methodology also incorporated sensitivity checks and peer review by subject-matter experts to ensure interpretations remained robust and defensible.

Limitations of the approach are acknowledged, including the inherent variability of jurisdictional reimbursement processes and the evolving nature of clinical evidence. Wherever applicable, assumptions were clearly documented and cross-checked with stakeholders to minimize bias. Ethical research practices governed respondent recruitment and data handling, ensuring confidentiality and compliance with applicable standards.

A decisive synthesis highlighting the necessity of integrated clinical, commercial, and operational approaches to secure patient access and sustain therapeutic adoption

In conclusion, the current environment for enzalutamide tablets is defined by converging clinical advances, shifting payer expectations, and heightened operational complexity driven by trade policy and distribution dynamics. Stakeholders that proactively align evidence generation with payer needs, bolster supply chain redundancy, and tailor commercial approaches to segmented end-user behaviors will be best positioned to maintain access and to support sustained patient outcomes. The interplay between clinical positioning, procurement mechanisms, and regional regulatory variation requires granular, country-specific execution plans supported by centralized strategic oversight.

Moreover, competitive differentiation increasingly depends on holistic value propositions that combine clinical efficacy with patient support, reliable supply, and adaptive contracting models. Organizations that invest in these integrated capabilities can mitigate downside risk from tariff volatility, tender outcomes, and competitive pressures while creating clearer pathways for long-term uptake. Continued monitoring of guideline developments, real-world evidence, and payer policy shifts will be essential to refine tactics and to preserve both clinical relevance and commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzalutamide Tablets Market, by Therapy Line

  • 8.1. First-Line Therapy
  • 8.2. Second-Line Therapy
  • 8.3. Third-Line Therapy

9. Enzalutamide Tablets Market, by End User

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Specialty Clinics
    • 9.3.1. Oncology Clinics
    • 9.3.2. Urology Clinics

10. Enzalutamide Tablets Market, by Indication

  • 10.1. Metastatic Castration-Resistant Prostate Cancer
  • 10.2. Metastatic Hormone-Sensitive Prostate Cancer
  • 10.3. Non-Metastatic Castration-Resistant Prostate Cancer

11. Enzalutamide Tablets Market, by Distribution Channel

  • 11.1. Online
    • 11.1.1. Manufacturer Websites
    • 11.1.2. eCommerce Platforms
  • 11.2. Offline

12. Enzalutamide Tablets Market, by Dosage Strength

  • 12.1. 120 mg
  • 12.2. 160 mg
  • 12.3. 40 mg
  • 12.4. 80 mg

13. Enzalutamide Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enzalutamide Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enzalutamide Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enzalutamide Tablets Market

17. China Enzalutamide Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alkem Laboratories Ltd.
  • 18.6. Astellas Pharma Inc.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Bayer AG
  • 18.9. Cadila Healthcare Limited
  • 18.10. Cipla Limited
  • 18.11. Dr. Reddy's Laboratories Ltd.
  • 18.12. Fresenius Kabi AG
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Hetero Labs Limited
  • 18.15. Intas Pharmaceuticals Ltd.
  • 18.16. Johnson & Johnson
  • 18.17. Lupin Limited
  • 18.18. Mylan N.V.
  • 18.19. Natco Pharma Limited
  • 18.20. Pfizer Inc.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Teva Pharmaceutical Industries Ltd.
  • 18.23. Torrent Pharmaceuticals Ltd.
  • 18.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZALUTAMIDE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZALUTAMIDE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY FIRST-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY FIRST-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SECOND-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SECOND-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THIRD-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THIRD-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ECOMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ECOMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ECOMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 120 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 120 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 120 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 160 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 160 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 160 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 80 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 80 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 80 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)